Sygnature Discovery have experience in the in vitro validation of novel disease modifying targets in multiple protein classes and across numerous therapeutic areas. Using our experience in tailored assay development Sygnature employs a multi-validation approach to understand the presumed role of the biological target.
Examples of approaches we can offer include:
- Expression profiling in both healthy and disease-relevant human cells
- Value-adding in vitro bioassays to measure biological activity of the target, characterise target pharmacology and assess the effects of modulating function
- Validation of target functional role(s) via modulation of target expression (CRISPR/siRNA/overexpression) modulation of phenotype upon alteration of target expression can be assessed using a variety of in-house technology platforms such as the IncuCyte ZOOM and Luminex